Healthcare resource utilization of spinal muscular atrophy in the Brazilian Unified Health System: a retrospective database study

Barbour, Julio; Araújo, Alexandra Prufer de Queiroz Campos; Zanoteli, Edmar; França Junior, Marcondes Cavalcante; Ritter, Alessandra Mileni Versuti; Casarin, Fabiana; Julian, Guilherme Silva; Yazawa, Priscila; Mata, Veronica Elisabeth; Carlos, Nayara da Silva.
J. bras. econ. saúde (Impr.) ; 13(2)Agosto/2021.
Artículo en Inglés | LILACS, ECOS | ID: biblio-1291960

Documentos relacionados

  1. [Personalized treatment options for spinal muscular atrophy].
  2. Financial cost and quality of life of patients with spinal muscular atrophy identified by symptoms or newborn screening.
  3. Health Care Resource Utilization and Costs for Patients with Spinal Muscular Atrophy: Findings from a Retrospective US Claims Database Analysis.
  4. Consensus from the Brazilian Academy of Neurology for the diagnosis, genetic counseling, and use of disease-modifying therapies in 5q spinal muscular atrophy.
  5. [Combination of modifying therapies in type 2 spinal muscular atrophy].
  6. Counteracting chromatin effects of a splicing-correcting antisense oligonucleotide improves its therapeutic efficacy in spinal muscular atrophy.
  7. Intrathecal Administration of Nusinersen in Pediatric SMA Patients with and without Spine Deformities: Experiences and Challenges over 3 Years in a Single Center.
  8. Splicing-Correcting Therapy for SMA.
  9. Management of Spinal Muscular Atrophy in the Adult Population.
  10. [Expert consensus on newborn screening for spinal muscular atrophy (2023 edition)].